Search

Displaying results 5691 - 5700 of 7604 in total
  1. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).

  2. Drug

    Salacetamide

    go.drugbank.com/drugs/DB20217
    Investigational

    Salacetamide is under investigation in clinical trial NCT00220285 (Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma).

  3. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat is under investigation in clinical trial NCT04556760 (Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

  4. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  5. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    It is added to food products as a flavoring agent.

  6. Drug

    Benziodarone

    go.drugbank.com/drugs/DB13277
    ApprovedWithdrawn

    It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].

  7. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

  8. Drug

    Vercirnon

    go.drugbank.com/drugs/DB15250
    Investigational

    Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial ...

  9. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    compared to interferon and ribavirin alone. … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  10. Drug

    Piritramide

    go.drugbank.com/drugs/DB12492
    ApprovedWithdrawn

    Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome